What is the recommended dose of Kafosid (Rifampicin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Kafosid (Rifampicin) Dosing

The recommended dose of rifampicin for tuberculosis treatment in adults is 10 mg/kg daily (maximum 600 mg) given as a single daily dose, or 10 mg/kg (maximum 600 mg) when given twice weekly or three times weekly as part of directly observed therapy. 1

Standard Dosing Regimens

Daily Therapy

  • Adults: 10 mg/kg daily with a maximum dose of 600 mg 1
  • Children: 10-20 mg/kg daily with a maximum dose of 600 mg 1
  • Rifampicin should preferably be taken on an empty stomach, though it may be administered with food in patients with gastrointestinal intolerance 1

Intermittent Therapy (Directly Observed)

  • Twice weekly: 10 mg/kg (maximum 600 mg) 1
  • Three times weekly: 10 mg/kg (maximum 600 mg) 1
  • All intermittent dosing regimens should be administered under directly observed therapy (DOT) 1

Special Populations

HIV-Infected Patients

  • Standard dose: 600 mg daily for tuberculosis prophylaxis (4 months duration) 1
  • Important caveat: Rifampin should usually not be coadministered with protease inhibitors and should not be coadministered with non-nucleoside reverse transcriptase inhibitors except for efavirenz 1
  • Rifabutin can be substituted for rifampin when drug interactions are problematic, though rifabutin is contraindicated with ritonavir, hard-gel saquinavir, and delavirdine 1

Pediatric Dosing

  • Daily: 10-20 mg/kg (maximum 600 mg) 1
  • Twice weekly: 10-20 mg/kg (maximum 600 mg) 1
  • Pediatric doses should not exceed normal adult doses 1

Renal Impairment

  • No specific dose adjustment is typically required for rifampicin in renal impairment, as it is primarily eliminated through biliary excretion 2
  • However, in patients with combined hepatic and renal dysfunction, elimination may be slower 2

Pharmacokinetic Considerations

Absorption and Distribution

  • Peak serum concentrations of approximately 10 μg/mL occur 2 hours after a 600 mg oral dose 2
  • The half-life is approximately 2.5 hours with a 600 mg dose 2
  • Approximately 80% of rifampicin is protein-bound, mainly to albumin 2

Dose-Dependent Kinetics

  • Critical point: With doses of 300-450 mg, the hepatic excretory capacity becomes saturated, resulting in more than proportional increases in serum concentrations with higher doses 2
  • On repeated administration, autoinduction of metabolism occurs, increasing the rate of drug elimination and reducing half-life 2

Intravenous Administration

  • Usual daily dose: 450-600 mg administered by IV bolus or IV drip infusion 3
  • IV formulation is reserved for critically ill or comatose patients, or those with gastrointestinal absorption problems 3
  • Treatment duration ranged from 1-113 days in clinical experience 3

Common Pitfalls and Monitoring

Drug Interactions

  • Rifampicin has multiple potential drug interactions due to its potent induction of hepatic enzymes 1
  • Particular attention must be paid to antiretroviral therapy compatibility 1

Adverse Effects

  • May cause reddish to brown-orange discoloration of urine, feces, saliva, sweat, skin, and tears (can discolor soft contact lenses) 1
  • Rifampicin competes with bilirubin for biliary excretion, potentially causing transient and reversible increases in bilirubin retention 2
  • Hepatotoxicity is dose-related and requires monitoring 1

Administration Timing

  • Should be taken with a full glass of water 1
  • Preferably on an empty stomach for optimal absorption 1

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.